HCT_116_CombinationTherapy_Pooled_Project__ENU_Mutagenesis. HCT_116_CombinationTherapy_Pooled_Project__ENU_Mutagenesis

KRAS mutant CRC is currently in clinical trial with a combination of a MEK and Akt inhibitor. These patients will likely develop resistance to this combination. We aim to identify the mechanisms of resistance via ENU mutagenesis, with a view to identifying additional therapeutics which have the ability to overcome this resistance.